Psoriasis

ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, according to a speaker at the American Academy of Dermatology Annual Meeting.

ORLANDO — Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse events, according to a speaker at the American Academy of Dermatology Annual Meeting.

ORLANDO — Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, according to a late-breaking presentation at the American Academy of Dermatology Annual Meeting.

ORLANDO — A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy of Dermatology Annual Meeting.

ORLANDO — Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, according to a presentation at the American Academy of Dermatology Annual Meeting.

In this exclusive video, Lawrence F. Eichenfield, MD, a member of the Healio Dermatology Peer Perspective Board, discusses psoriasis case reports presented at Maui Derm 2025.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, discusses areas of unmet need in the field of psoriasis.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025.

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.